SCHEMBL3011298

SCHEMBL3011298

CC(C)c1cc(C(C)C)c(S(=O)(=O)N2CCN(c3nc(-c4ccc(Cl)cc4)cs3)CC2)c(C(C)C)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.55
SMN1; SMN2 Q16637 5/20 0.53
MAPK1 P28482 5/20 0.53
LMNA P02545 5/20 0.53
ALDH1A1 P00352 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 2/20 0.43
HTT P42858 1/20 0.43
FABP4 P15090 1/20 0.43
USP2 O75604 1/20 0.43
RECQL P46063 1/20 0.43
AR P10275 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3653671 0.91 MAPT (0.47) MAPTSMN1; SMN2MAPK1LMNAALDH1A1
SCHEMBL3018623 0.91 AR (0.53) MAPTSMN1; SMN2MAPK1LMNAALDH1A1
SCHEMBL3017577 0.91 SMN1; SMN2 (0.53) MAPTSMN1; SMN2MAPK1LMNAALDH1A1
SCHEMBL3009218 0.91 SMN1; SMN2 (0.45) MAPTSMN1; SMN2MAPK1LMNAALDH1A1
SCHEMBL3001185 0.91 SMN1; SMN2 (0.51) MAPTSMN1; SMN2MAPK1LMNAALDH1A1
SCHEMBL3021331 0.90 MAPK1 (0.62) MAPTSMN1; SMN2MAPK1LMNAALDH1A1
SCHEMBL3013827 0.89 SMN1; SMN2 (0.51) MAPTSMN1; SMN2MAPK1LMNAALDH1A1
SCHEMBL3013054 0.89 AR (0.54) MAPTSMN1; SMN2MAPK1LMNAALDH1A1
SCHEMBL3005952 0.89 LMNA (0.53) MAPTSMN1; SMN2MAPK1LMNAALDH1A1
SCHEMBL3013793 0.89 SMN1; SMN2 (0.53) MAPTSMN1; SMN2MAPK1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885SMN1; SMN2 1/4885MAPK1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.